Hu­mi­ra biosim­i­lar mar­ket re­mains stag­nant, with Ab­b­Vie los­ing on­ly 2% of mar­ket share, Sam­sung re­port shows

Ab­b­Vie is show­ing off to the world how it’s main­tain­ing most of the sales vol­ume for the Hu­mi­ra (adal­i­mum­ab) fran­chise in the US, los­ing just 2% of mar­ket share since sev­er­al biosim­i­lars launched in Ju­ly, ac­cord­ing to a new Sam­sung Bioepis biosim­i­lars re­port.

The biosim­i­lar mar­ket for Hu­mi­ra has re­mained stag­nant, even with new en­trants and low­er prices. Three of the nine Hu­mi­ra biosim­i­lars cur­rent­ly mar­ket­ed are priced about 85% less than Hu­mi­ra’s whole­sale ac­qui­si­tion cost (WAC).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER